Skip to main content
Premium Trial:

Request an Annual Quote

This TB Screen Is Furry and Has a Tail

Belgian non-governmental organization Apopo has been testing the African giant pouched rat as a pulmonary tuberculosis testing method in Tanzania, and the results have been so promising that the Mozambique government has asked Apopo to implement a similar project there, The Hindu reports.

The newspaper adds that Apopo has screened more than 97,000 samples in hospitals where the rats are being used as a secondary screening method, and detection rates have improved by 23 percent. In addition, the rats can screen about 1,680 samples each day, compared to 40 samples a day that a lab technician can perform using a microscope.

The African giant pouched rats — named for their paunchy cheek pouches — are only distantly related to true rats. They measure about nine to 18 inches in length and have tails about 14 to 18 inches in length. Apopo trained the animals to detect the tuberculosis bacteria, which produces distinctive organic compounds found in infected samples.

This isn't the first case of the animal kingdom being used to diagnose human disease. Dogs also are being trained to sniff out a variety of cancers, including lung cancer, breast cancer, and colon cancer.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.